IPSEN (OTCMKTS:IPSEY) Shares Gap Down – What’s Next?

IPSEN (OTCMKTS:IPSEY) gapped down prior to trading on Thursday . The stock had previously closed at $46.2280, but opened at $44.82. IPSEN shares last traded at $44.82, with a volume of 125 shares trading hands.

Wall Street Analyst Weigh In

IPSEY has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Barclays downgraded IPSEN from an “equal weight” rating to an “underweight” rating in a research note on Tuesday, September 8th. Finally, Zacks Research raised IPSEN to a “hold” rating in a report on Friday, May 29th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, IPSEN has a consensus rating of “Reduce”.

IPSEN Trading Down 3.2%

The company’s fifty day simple moving average is $46.47 and its two-hundred day simple moving average is $46.74.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.